Downloads
- March Cytiva Webinar 3/11/2026
-
Ask The Pros — The Latest In Upstream HCP Mitigation
1/5/2026
We asked leading experts how upstream interventions can reshape HCP control. Here’s what they shared. Answers have been edited for clarity.
-
2026 CDMO Forecast: The 7 Shifts Sponsors Need To Prepare For
1/5/2026
2026 is shaping up to be a year in which operational discipline, strategic alignment, and regulatory preparedness will differentiate high-performing sponsors from those facing avoidable delays.
-
Biosimilar Manufacturing Complexity Demands Mastery, Not Mimicry
1/5/2026
GlycoNex's denosumab biosimilar development experience illustrates how a "just copy it" approach is an insufficient strategy in modern biomanufacturing.
-
The Pressure To Accelerate Innovate Fast Is Mounting
1/2/2026
In this segment from the Bioprocess Online Live event “How Digital Tools Are Accelerating Biopharma Development,” panelists Moiz Diwan, Ph.D. (AbbVie), and Kat Kozyrytska (independent technology consultant) reflect on the increasing need to reduce timelines and improve process robustness and productivity, all while modalities grow in complexity. This pressure to innovate and boost efficiency is mounting, and they see technological tools like automation, digitalization, and modeling as the keys to surviving in this new paradigm.
-
Understanding AbbVie's Lab-In-A-Loop Development Model
1/2/2026
In this segment from the Bioprocess Online Live event “How Digital Tools Are Accelerating Biopharma Development,” AbbVie’s head of biologics purification development and digitization teams, Moiz Diwan, Ph.D., explains the company’s lab-in-a-loop concept, which combines human intelligence with AI and other digital tools to streamline workflows and reduce development time by 50%.
-
Automating Data Capture
1/2/2026
In this segment from the Bioprocess Online Live event “How Digital Tools Are Accelerating Biopharma Development,” independent technology consultant Kat Kozyrytska reacts to an audience poll suggesting that automated data capturing would have the biggest impact on operations. She sees this as an opportunity in the industry ripe for innovation and collaboration.
-
Why Biopharma's Tech Adoption Seems Slow
1/2/2026
Biopharma is a relatively conservative and highly regulated industry, which means change happens slowly. In this segment from the Bioprocess Online Live event “How Digital Tools Are Accelerating Biopharma Development,” panelists Moiz Diwan, Ph.D. (AbbVie), and Kat Kozyrytska (independent technology consultant) discuss the factors slowing biopharma’s adoption of advanced technologies compared to other sectors and advocate for industry-wide collaboration to move the industry forward.
-
What Will Allow For True Digital Twins?
1/2/2026
In this segment from the Bioprocess Online Live event “How Digital Tools Are Accelerating Biopharma Development,” panelists Moiz Diwan, Ph.D. (AbbVie), and Kat Kozyrytska (independent technology consultant) consider the factors that need to come together to actualize digital twins for process development.
-
How To Strategically Integrate New Technology Into Existing Workflows
1/2/2026
The majority of our audience indicated that integrating digital tools into existing workflows was the biggest challenge in adopting new technologies. In this segment from the Bioprocess Online Live event “How Digital Tools Are Accelerating Biopharma Development,” AbbVie’s head of biologics purification development and digitization teams, Moiz Diwan, Ph.D., and independent technology consultant Kat Kozyrytska share advice on how organizations can approach technology adoption and implementation.